HoneyBear Biosciences, Inc.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
Utilizing the innovative CO-NECTAR® glycan-conjugation technology to develop novel ADC drugs and help patients fight against diseases. With an aging population, the number of cancer patients is on the rise. Given that many late-stage cancer patients often face dilemmas such as poor drug efficacy, excessive toxicity, drug resistance developed during treatment, or even the lack of available drugs, and with many emerging diseases continuously arising recently, there is an urgent clinical need for more and better drugs to help patients alleviate the impact of their illnesses. The ADC drugs produced using the innovative CO-NECTAR® glycan-conjugation technology developed by HoneyBear Biosciences, Inc. are expected to overcome the aforementioned limitations of drug use, thereby benefiting more cancer patients.
Furthermore, this technology can be further expanded to other therapeutic categories, such as the preparation of radiopharmaceuticals, immunomodulators, and other formulations, enabling patients with various diseases to receive more precise treatments. HoneyBear Biosciences, Inc. truly takes it as its mission to become a pioneer in precision medicine.
(The content above was translated by AI.)
Furthermore, this technology can be further expanded to other therapeutic categories, such as the preparation of radiopharmaceuticals, immunomodulators, and other formulations, enabling patients with various diseases to receive more precise treatments. HoneyBear Biosciences, Inc. truly takes it as its mission to become a pioneer in precision medicine.
(The content above was translated by AI.)
Founded Year
2021
Unified Business No.
91007214
Status
Active
Number of Employees
5
Total Paid-in
Capital
675,784,140 (NT$)
Location of Company
Taiwan
, Taipei City
Overseas Development
Singapore
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
HoneyBear Jiaheng Biotechnology was founded in 2021 and is dedicated to antibody-related new technology platforms and novel drug development, with a particular focus on the research of antibody-drug conjugates (ADC). In 2022, Jiaheng Biotech completed the technology transfer of the highly specific conjugation technology platform and antibody-drug conjugate drugs from the Development Center for Biotechnology. Currently, the company is actively promoting its world-class competitive CO-NECTAR® technology platform into the market and developing clinical applications. At the same time, Jiaheng Biotech continues to invest in innovation, aiming to introduce more new technologies, accelerate novel drug development, and benefit patients.
Jiaheng Biotech's platform and product development strategy is global market-oriented. Utilizing Taiwan's high-quality R&D talent, technology, and capital, the company develops biopharmaceutical products with broad market potential. With a foothold in Taiwan and a global vision, Jiaheng Biotech strives to become an international-class novel drug development company.
(The content above was translated by AI.)
Jiaheng Biotech's platform and product development strategy is global market-oriented. Utilizing Taiwan's high-quality R&D talent, technology, and capital, the company develops biopharmaceutical products with broad market potential. With a foothold in Taiwan and a global vision, Jiaheng Biotech strives to become an international-class novel drug development company.
(The content above was translated by AI.)
